


Cortellis Clinical Trials Intelligence

Tips for tracking the impact of COVID-19 on clinical research and help you navigate the uncertainties ahead


Track clinical trials that are suspended or with delayed patient enrollment due to COVID-19

1. Type **Covid-19 AND (delay OR halt OR pause OR postpone)** in the Quick Search box and click the **Full Text** search button



The screenshot shows a search bar with a dropdown menu set to 'All'. The search query is 'Covid-19 AND (delay OR halt OR pause OR postpone)'. To the right of the search bar are two buttons: 'Index' and 'Full Text', both with magnifying glass icons.

2. Under Report Type (on the left panel), switch to **Clinical Trials**, then click the **Show all Filters** link below Condition.



The screenshot shows a filter panel with a 'Condition' section. It contains three checkboxes: 'Coronavirus disease 19 infection (13)', 'Multiple myeloma (6)', and 'Acute myelogenous leukemia (4)'. Below the checkboxes is a 'Show all filters' button.

3. Scroll to the last filter to define the **Last Change Date** from **January 1, 2020** and leave the to blank. Apply the filters.

Optional Filters: You may also select clinical trials in your **Conditions** of interest or those from specific **Sponsors**. If you switch the **Recruitment Status** filter, you will see which clinical studies officially got **Suspended** or **Terminated**, as well as **Planned** studies that are now delayed due to COVID-19.

4. On the Search Results* page, click on the **List View** thumbnail (on the top right) then **Show hit fields*** to view where the search terms appear in each report. You may also **Sort by Last Change Date** of **Most Recent**.

Use the **Save and Alert** feature to receive email notifications on any clinical trials that get disrupted, as well as any adjustments to the protocol and estimated end dates.

Search Results

104 results found for full text search for the search term 'Covid-19 AND (delay OR halt OR pause OR postpone)' with filter(s) applied: From 01-Jan-2020

Results Per page: 10 Sort by: Last Change Date Most Recent

View [Grid] [List] [Table] [Compare]

Hide hit fields

Conalescent Antibodies Infusion in Critically Ill COVID 19 Patients

Phase: Phase Not Applicable
 Recruitment Status: Not yet recruiting
 Reason for Trial Discontinuation:
 DFPP procedure from consenting donors and infused in one critically ill, ventilated patient with COVID 19 pneumonia.... Patient being treated with other anti-COVID-19 e treatments....donation Informed consent Recipients: Adult (> 18-year-old) men and women COVID-19 pneumonia diagnosed by standard criteria Need of ventilator support consent for participation
 Indications: Coronavirus disease 19 infection
 Indications Tree: Coronavirus disease 19 infection
 Aims & Scope: This pilot study aims to explore whether the infusion of antibodies obtained with one single DFPP (double-filtration plasmapheresis) procedure from volu convalescent donors offers an effective and safe therapeutic option for critically ill patients with severe coronavirus (COVID-19) pneumonia requiring mechanical ventila
 Exclusion Criteria Text/Exclusion Criteria Index: Patient being treated with other anti-COVID-19 experimental treatments
 Inclusion Criteria Text/Inclusion Criteria Index: Previous COVID-19 pneumonia No evidence of active disease Being eligible for plasma Ig donation Informed consent Recipients: Adult (> 18-year-old) men and women COVID-19 pneumonia diagnosed by standard criteria Need of ventilator support Informed consent... an informed consent and an authorized representative is not available without a delay that would, in the opinion of the Investigator, compromise the potential life-saving effect of the treatment this can be administered without consent.
 Consent
 Identifiers: DFPP COVID 19
 Protocol Description Text: Anti-coronavirus antibodies (immunoglobulins) obtained with DFPP from convalescent donors will be administered to ten consecutive patients who fulfill the inclusion criteria. Convalescent antibodies will be obtained with one DFPP procedure from consenting donors and infused in one critically ill, ventilated patient with COVID 19 pneumonia.
 Extract: DFPP procedure from consenting donors and infused in one critically ill, ventilated patient with COVID 19 pneumonia.... Patient being treated with other anti-COVID-19 experimental treatments....donation Informed consent Recipients: Adult (> 18-year-old) men and women COVID-19 pneumonia diagnosed by standard criteria Need of ventilator support Informed consent for participation
 Title: Conalescent Antibodies Infusion in Critically Ill COVID 19 Patients
 Scientific Title: A Pilot Study to Explore the Efficacy and Safety of Rescue Therapy With Antibodies From Convalescent Patients Obtained With Double-Filtration Plasmapheresis (DFPP) and Infused in Critically Ill Ventilated Patients With Coronavirus Disease 2019 (COVID-19)

Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis

Phase: Phase 1b Clinical
 Recruitment Status: Not yet recruiting
 Reason for Trial Discontinuation:
 aeruginosa. The study would evaluate the safety, pharmacokinetics, pharmacodynamics, and biological activity of CB-280 in approximately (n = 32) adult patients with cystic fibrosis. In April 2020, there would be a delay in the enrollement of first patient until the third quarter of 2020 due to COVID-19 pandemic situation [2265820].
 Aims & Scope: This was a phase 1b, multiple ascending dose-escalation study to evaluate the safety and tolerability of arginase inhibitor CB-280 in patients with cystic fibrosis. The study CX-280-202 was a phase 1b, randomized, double-blind, placebo-controlled, multiple ascending dose-escalation study of CB-280 in adult patients with cystic fibrosis and chronic infection with pseudomonas aeruginosa. The study would evaluate the safety, pharmacokinetics, pharmacodynamics, and biological activity of CB-280 in approximately (n = 32) adult patients with cystic fibrosis. In April 2020, there would be a delay in the enrollement of first patient until the third quarter of 2020 due to COVID-19 pandemic situation [2265820].
 Extract: aeruginosa. The study would evaluate the safety, pharmacokinetics, pharmacodynamics, and biological activity of CB-280 in approximately (n = 32) adult patients with cystic fibrosis. In April 2020, there would be a delay in the enrollement of first patient until the third quarter of 2020 due to COVID-19 pandemic situation [2265820].

List View

Receive an email alert when Clinical Trials that match your criteria are added or updated.

1. Explore the results.
 This will include Suspended or Terminated clinical trials and even Planned studies that have been delayed, as well as treatments in development for **Coronavirus disease 19 infection**.
2. To view comments regarding the type of impact on these trials, under **Protocols & Results**, go to the **Aims & Scope** section. You may also search (Ctrl +F) for where **COVID-19** is mentioned.

< Back | Forward > Clinical Trial Report Alert Download

◀ Prev Next ▶

Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis

Snapshot	Highlight <input type="checkbox"/> Search Terms & Synonyms	< Previous	Next >
Protocol & Results	PROTOCOL & RESULTS		
■ Aims & Scope	AIMS & SCOPE		
■ Protocol Description	This was a phase Ib, multiple ascending dose-escalation study to evaluate the safety and tolerability of arginase inhibitor CB-280 in patients with chronic infection with <i>Pseudomonas aeruginosa</i> .		
■ Regimens	The study CX-280-202 was a phase Ib, randomized, double-blind, placebo-controlled, multiple ascending dose-escalation study of CB-280 in 32 adult patients with cystic fibrosis.		
■ Results	In April 2020, there would be a delay in the enrolment of first patient until the third quarter of 2020 due to COVID-19 pandemic situation [2265820].		
■ Adverse Events	PROTOCOL DESCRIPTION TEXT		
■ Treatment	There would be four planned sequential dose-escalation, cohorts of eight patients each, randomized 6 : 2 to receive CB-280 or matched placebo at doses of 50, 100, 200, or 400 mg po, administered bid for 14 days and placebo twice-daily for 14 days. Intermediate dose levels might be evaluated based on emerging safety data at the planned dose levels.		
Subjects & Measurements			
Registry Contacts & Sites			
Change History			
Sources			

PRESS RELEASE

14-Apr-2020
Calithera Biosciences Provides Update on Business Operations
 Calithera Biosciences Inc
 Source ID: 2265820

[View full report](#)

- Click on the blue reference numbers to see the source. For Press Releases, you may review the full report in Cortellis to get more details such as what measures the company is taking, any new data read out dates, etc.

Calithera Biosciences Provides Update on Business Operations

Snapshot	Highlight <input type="checkbox"/> Search Terms & Synonyms	< Previous	Next >
Full Text	FULL TEXT		
	<p>April 14, 2020 07:00 ET Source: Calithera Biosciences, Inc.</p> <p>SOUTH SAN FRANCISCO, April 14, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, shared an update on business operations, including clinical program adjustments related to COVID-19.</p> <p>"Our first priority during the COVID-19 pandemic is the health of our employees, as well as patients and medical professionals involved in our clinical programs. We are continuing all clinical operations, with additional COVID-19 related safety measures in place. Given the fluid nature of the current situation, and the impact of the pandemic on clinical sites globally, we are delaying the start of enrollment of patients in our two new clinical trials, while we work towards accelerating the opening of sites," said Susan Molineaux, president and chief executive officer of Calithera. "We believe we are on track to announce top-line CANTATA results this year, and we are narrowing the timeframe to the fourth quarter of 2020."</p> <p>Clinical programs update:</p> <p>Randomized CANTATA trial of telaglenastat and cabozantinib in advanced renal cell carcinoma. The CANTATA trial was fully enrolled in October 2019 and Calithera advised at that time that the company planned to report top-line efficacy and safety data from the trial in the second half of 2020, and more recently guided towards late third quarter or fourth quarter of 2020. In light of COVID-19, Calithera now expects top-line data in the fourth quarter of 2020. Calithera has made accommodations to facilitate study conduct during the pandemic, including allowing patients to have scans performed at local clinical centers to facilitate compliance with the study schedule of assessments, and to receive a larger allocation of study drug in order to reduce the number of visits required to the clinical site, if necessary. While affirming that the readout is expected by the end of 2020, the updated guidance allows for additional time for activities that require visits to clinical sites, including data monitoring.</p> <p>Randomized KEAPSAKE trial in non-small cell lung cancer (NSCLC) patients with genetic mutation NRF2/KEAP1. The randomized Phase 2 trial of telaglenastat for the treatment of lung cancer continues to progress towards multiple site openings. However, given the challenges associated with opening new clinical studies during the current stage of the COVID-19 pandemic, Calithera expects to delay enrollment of the first patient until the third quarter of 2020, pending further developments in the COVID-19 situation. Calithera plans to present interim data from this trial in 2021.</p>		

For more information or to request for a guided workflow review, contact Customer Service at **LS Product Support**.